IL6R and COVID-19: The clinical efficacy of anti-IL-6R in COVID-19 patients has been tested in a recent randomized, double-blind phase III COVACTA trial (NCT04320615; clinicaltrials.gov) but showed an insignificant decrease in fatality [67].